Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $10,899,350.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $65.56, for a total value of $10,899,350.00. Following the completion of the transaction, the chief executive officer directly owned 8,941,533 shares in the company, valued at approximately $586,206,903.48. This represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tempus AI Stock Down 5.8%

Tempus AI stock opened at $59.82 on Monday. The firm has a market cap of $10.64 billion, a price-to-earnings ratio of -50.27 and a beta of 5.22. Tempus AI, Inc. has a 52-week low of $36.22 and a 52-week high of $104.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. The firm has a 50 day moving average price of $68.56 and a two-hundred day moving average price of $74.12.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. During the same period in the prior year, the company posted ($0.46) earnings per share. Tempus AI’s revenue for the quarter was up 84.7% compared to the same quarter last year. Equities analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on TEM. HC Wainwright decreased their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research note on Friday, November 7th. TD Cowen downgraded shares of Tempus AI from a “buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Canaccord Genuity Group lowered their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. Morgan Stanley increased their target price on shares of Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Finally, JPMorgan Chase & Co. decreased their price target on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, December 15th. Six equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $87.20.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Cranbrook Wealth Management LLC bought a new stake in Tempus AI during the 3rd quarter worth approximately $25,000. Concord Wealth Partners boosted its position in shares of Tempus AI by 308.0% during the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock valued at $26,000 after buying an additional 308 shares during the last quarter. JPL Wealth Management LLC bought a new stake in Tempus AI during the third quarter worth $26,000. GAMMA Investing LLC purchased a new stake in Tempus AI in the 3rd quarter valued at $28,000. Finally, Allworth Financial LP lifted its stake in Tempus AI by 5,000.0% during the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.